DAFTAR PUSTAKA

Aktaran Ş, Akarsu E, Erbağci İ, Araz M, Okumuş S, Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy: IVGC vs. OGC in Graves' ophthalmopathy. Int J Clin Pract. 2006 Aug 2;61(1):45–51.

Aranyosi, J. K., Galgoczi, E., Erdei, A., Katko, M., Fodor, M., Ujhelyi, Z., Bacskay, I., Nagy, E. V., & Ujhelyi, B. (2022). Different Effects of Cigarette Smoke, Heated Tobacco Product and E-Cigarette Vapour on Orbital Fibroblasts in Graves' Orbitopathy; a Study by Real Time Cell Electronic Sensing. Molecules (Basel, Switzerland), 27(9), 3001. https://doi.org/10.3390/molecules27093001

Bahn, R. S. (2010) 'Graves' ophthalmopathy', New England Journal of Medicine, 362(8), pp. 726–738.

Barbesino, G. and Tomer, Y. (2013) 'Clinical Utility of TSH Receptor Antibodies', The Journal of Clinical Endocrinology and Metabolism, 98(6), pp. 2247–2255. doi: 10.1210/jc.2012-4309.

Barrio-Barrio, J., Sabater, Alfonso L, et al. (2015) 'Graves' ophthalmopathy: VISA versus EUGOGO classification, assessment, and management', Journal of ophthalmology, 2015.

Barrio-Barrio, J., Sabater, Alfonso L., et al. (2015) 'Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management', Journal of Ophthalmology, 2015, p. e249125. doi: 10.1155/2015/249125.

Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, et al. Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy. J Clin Endocrinol Metab. 2012 Dec 1;97(12):4454–63.

Bartalena, L. et al. (2016) 'The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy', European Thyroid Journal, 5(1), pp. 9–26. doi: 10.1159/000443828.

Bartalena, L. et al. (2021) 'The 2021 European Group on Graves' Orbitopathy (EUGOGO) Clinical Practice Guidelines for the Medical Management of Graves' Orbitopathy', European Thyroid Journal.

Cawood, T., Moriarty, P. and O'Shea, D. (2004) 'Recent developments in thyroid eye disease', Bmj, 329(7462), pp. 385–390.

Cirić, J. et al. (2000) '[Treatment of Grave's ophthalmopathy with high doses of corticosteroids]', Srpski Arhiv Za Celokupno Lekarstvo, 128(5–6), pp. 179–183.

Diana, T. and Kahaly, G. J. (2018) 'Thyroid Stimulating Hormone Receptor Antibodies in Thyroid Eye Disease—Methodology and Clinical Applications', Ophthalmic Plastic & Reconstructive Surgery, 34(4S), pp. S13–S19.

Diana, T., Ponto, K. and Kahaly, G. (2020) 'Thyrotropin receptor antibodies and Graves' orbitopathy', Journal of Endocrinological Investigation, pp. 1–10.

Dik, W. A., Virakul, S. and van Steensel, L. (2016) 'Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy', Experimental eye research, 142, pp. 83–91.

Dosiou, C. & Kossler, A. L. 2021. Thyroid Eye Disease: Navigating the New Treatment Landscape. Journal of the Endocrine Society, 5, bvab034-bvab34.

Douglas, R. S. and Gupta, S. (2011) 'The pathophysiology of thyroid eye disease: implications for immunotherapy', Current opinion in ophthalmology, 22(5), pp. 385–390.

Dutta D, Ghosh S, Mukhopadhyay P, Mukhopadhyay S, Chowdhury S, Roy A. Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves′ orbitopathy: A randomized controlled trial. Indian J Endocrinol Metab. 2015;19(3):351.

FitzPatrick A. M. (2022). Is Estrogen a Missing Culprit in Thyroid Eye Disease? Sex Steroid Hormone Homeostasis Is Key to Other Fibrogenic Autoimmune Diseases - Why Not This One?. Frontiers in immunology, 13, 898138. https://doi.org/10.3389/fimmu.2022.898138

Fox, T. J. and Anastasopoulou, C. (2021) Graves Orbitopathy, StatPearls [Internet]. StatPearls Publishing. Available at : https://www.ncbi.nlm.nih.gov/books/NBK549889/ (Accessed: 1 July 2021).

Gaballa, S. A., Kompella, U. B., Elgarhy, O., Alqahtani, A. M., Pierscionek, B., Alany, R. G., & Abdelkader, H. (2021). Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug delivery and translational research, 11(3), 866–893. https://doi.org/10.1007/s13346-020-00843-z

Gontarz-Nowak, K. et al. (2021) 'Current Knowledge on Graves' Orbitopathy', Journal of Clinical Medicine, 10(1), p. 16.

He Y, Mu K, Liu R, Zhang J, Xiang N. Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves’ ophthalmopathy: a prospective, randomized controlled trial. Endocr J. 2017;64(2):141–9.

Hoppe, E., Lee, A. C. H., Hoppe, D. & Kahaly, G. J. 2020. Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial. European Thyroid Journal, 9, 313-20.

Hu, Y., Man, Y., Sun, X. & Xue, Y. 2021. Effects of glucocorticoid pulse therapy on thyroid function and thyroid antibodies in children with graves' disease. Italian Journal of Pediatrics, 47, 46.

Insull, E. A. et al. (2019) 'Early low- dose rituximab for active thyroid eye disease: An effective and well- tolerated treatment', Clinical endocrinology, 91(1), pp. 179–186.

Iyer, S. and Bahn, R. (2012) 'Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor', Best practice & research. Clinical endocrinology & metabolism, 26(3), pp. 281–289. doi: 10.1016/j.beem.2011.10.003.

Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves' Orbitopathy. J Clin Endocrinol Metab. 2005 Sep;90(9):5234–40.

Kim, S. J., Kim, M. J., Yoon, S. G., Myong, J. P., Yu, H. W., Chai, Y. J., Choi, J. Y., & Lee, K. E. (2019). Impact of smoking on thyroid gland: dose-related effect of urinary cotinine levels on thyroid function and thyroid autoimmunity. Scientific reports, 9(1), 4213. https://doi.org/10.1038/s41598-019-40708-1

Łacheta, D. et al. (2019) 'Immunological aspects of graves' ophthalmopathy', BioMed research international, 2019.

Längericht, J., Krämer, I. & Kahaly, G. J. 2020. Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application. Therapeutic advances in endocrinology and metabolism, 11, 2042018820958335-35.

Längericht, J., Krämer, I., & Kahaly, G. J. (2020). Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application. Therapeutic advances in endocrinology and metabolism, 11, 2042018820958335. https://doi.org/10.1177/2042018820958335

Le Moli, R. et al. (2020) 'Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism', Frontiers in Endocrinology, 11. doi: 10.3389/fendo.2020.00367.

Liaboe, C. A. et al. (2016) 'Thyroid Eye Disease: An Introductory Tutorial and Overview of Disease', EyeRounds. org.

Ma, J. and Feng, Y. (2020) 'Thyroid-Associated Ophthalmopathy', in Integrative Ophthalmology. Springer, pp. 187–190.

Macchia, P. E. et al. (2001) 'High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy', Journal of Endocrinological Investigation, 24(3), pp. 152–158. doi: 10.1007/BF03343835.

Marcocci, C., & Marinò, M. (2012). Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy. Best practice & research. Clinical endocrinology & metabolism, 26(3), 325–337. https://doi.org/10.1016/j.beem.2011.11.005

Michalek, K. et al. (2009) 'TSH receptor autoantibodies', Autoimmunity reviews, 9(2), pp. 113–116.

Nabi, T. and Rafiq, N. (2020) 'Factors associated with severity of orbitopathy in patients with Graves' disease'.

Nicolì, F. et al. (2020) 'Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy', Journal of Endocrinological Investigation, pp. 1–5.

OpenEpi - Toolkit Shell for Developing New Applications (no date). Available at: http://openepi.com/SampleSize/SSMean.htm (Accessed: 16 April 2021).

Orgiazzi, J. (2000) 'Anti–Tsh Receptor Antibodies in Clinical Practice', Endocrinology and Metabolism Clinics of North America, 29(2), pp. 339–355.

Penta, L., Muzi, G., Cofini, M., Leonardi, A., Lanciotti, L., & Esposito, S. (2019). Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?. International journal of environmental research and public health, 16(1), 155. https://doi.org/10.3390/ijerph16010155

Pirahanchi, Y., Tariq, M. A. and Jialal, I. (2020) 'Physiology, thyroid', StatPearls [Internet].

Roos, J. C. P., Paulpandian, V. and Murthy, R. (2019) 'Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy', Eye, 33(2), pp. 212–217. doi: 10.1038/s41433-018-0242-9.

San Miguel, I., Arenas, M., Carmona, R., Rutllan, J., Medina-Rivero, F., & Lara, P. (2018). Review of the treatment of Graves' ophthalmopathy: The role of the new radiation techniques. Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society, 32(2), 139–145. https://doi.org/10.1016/j.sjopt.2017.09.003

Schlüter, A., Flögel, U., Diaz-Cano, S., Görtz, G. E., Stähr, K., Oeverhaus, M., Plöhn, S., Mattheis, S., Moeller, L. C., Lang, S., Bechrakis, N. E., Banga, J. P., Eckstein, A., & Berchner-Pfannschmidt, U. (2018). Graves' orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model. Scientific reports, 8(1), 13096. https://doi.org/10.1038/s41598-018-31253-4

Suh, S., & Park, M. K. (2017). Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem. Endocrinology and metabolism (Seoul, Korea), 32(2), 180–189. https://doi.org/10.3803/EnM.2017.32.2.180

Sullivan, J. 2008. Orbita. In: Riordan, P. & Whitcher, J. (eds.) Vaughan & Asburry Oftalmologi Umum. 17 ed. Jakarta: EGC.

Takasu, N. et al. (1997) 'Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects', Journal of endocrinological investigation, 20(8), pp. 452–461.

Tsirouki, T. et al. (2016) 'Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves' orbitopathy and analysis on who requires additional therapy, Clinical Ophthalmology, 10, pp. 2277–2289. doi: 10.2147/OPTH.S118555.

Tu, X., Dong, Y., Zhang, H. & Su, Q. 2018. Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis. BioMed Research International, 2018, 1-9.

Tu, X., Dong, Y., Zhang, H., & Su, Q. (2018). Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis. BioMed research international, 2018, 4845894. https://doi.org/10.1155/2018/4845894

Ugradar, S. and Rootman, D. B. (2019) 'Orbital fat expansion in thyroid eye disease is related to age', European Journal of Ophthalmology, p. 1120672119852322.

Vagefi, C. N. B., Bobby S. Korn, Keith D. Carter, Julian D. Perry, Pete Setabutr, Eric A. Steele, M. Reza (no date) 'Orbital Inflammatory and Infectious Disorders', in Oculofacial Plastic and Orbital Surgery. 2019th–2020th edn. American Academy of Ophthalmology, pp. 75–85.

Van Geest RJ, Sasim IV, Koppeschaar HPF, Kalmann R, Stravers SN, Bijlsma WR, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008 Feb;158(2):229–37.

Wakelkamp IMMJ, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf). 2005 Sep;63(3):323–8

Wiersinga, W. M. (2012) 'Quality of life in Graves' ophthalmopathy', Best Practice & Research. Clinical Endocrinology & Metabolism, 26(3), pp. 359–370. doi: 10.1016/j.beem.2011.11.001.

Yang, D. D., Gonzalez, M. O. and Durairaj, V. D. (2011) 'Medical management of thyroid eye disease', Saudi Journal of Ophthalmology, 25(1), pp. 3–13. doi: 10.1016/j.sjopt.2010.10.001.

Yeatts, R. P. (2005) 'Quality of life in patients with Graves ophthalmopathy', Transactions of the American Ophthalmological Society, 103, pp. 368–411.

Young, S. M. et al. (2019) 'Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease', Orbit, 38(5), pp. 362–369.

Zhu W, Ye L, Shen L, Jiao Q, Huang F, Han R, et al. A Prospective, Randomized Trial of Intravenous Glucocorticoids Therapy With Different Protocols for Patients With Graves' Ophthalmopathy. J Clin Endocrinol Metab. 2014 Jun 1;99(6):1999–2007.

Zloto, O., Sagiv, O., Priel, A., Cukierman-Yaffe, T., Tirosh, A., Agmon-Levin, N., Madgar, S., Serlin, T., & Ben Simon, G. (2021). Gender differences in clinical presentation and prognosis of thyroid eye disease. European journal of ophthalmology, 31(5), 2717–2723. https://doi.org/10.1177/1120672120964112

Gontarz-Nowak, K., Szychlińska, M., Matuszewski, W., Stefanowicz-Rutkowska, M., & Bandurska-Stankiewicz, E. (2020). Current Knowledge on Graves' Orbitopathy. Journal of clinical medicine, 10(1), 16. https://doi.org/10.3390/jcm10010016

Lampiran 1. Rekomendasi Persetujuan Etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari,.MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 673/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 2 Nopember 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22080416	No Sponsor Protokol	
Peneliti Utama	**dr. Ade Septriana**	Sponsor	
Judul Peneliti	PENGARUH PEMBERIAN KORTIKOSTEROID INTRAVENA DOSIS TINGGI TERHADAP AKTIVITAS PENYAKIT, TINGKAT KEPARAHAN PENYAKIT DAN KUALITAS HIDUP PASIEN GRAVES' OPHTHALMOPATHY DI RUMAH SAKIT UMUM PUSAT WAHIDIN SUDIROHUSODO MAKASSAR		
No Versi Protokol	**2**	Tanggal Versi	**31 Oktober 2022**
No Versi PSP	**2**	Tanggal Versi	**31 Oktober 2022**
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☐ Expedited ☒ Fullboard Tanggal **7 September 2022**	Masa Berlaku **2 Nopember 2022** sampai **2 Nopember 2023**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Formulir Persetujuan

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax :0411-581431

FORMULIR PERSETUJUAN SETELAH PENJELASAN

Saya yang bertandatangan di bawah ini :
Nama : .....
Umur : .....
Masa Kerja : .....
Satuan : .....
Alamat : .....
.....

setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat, dan apa yang akan dilakukan pada penelitian ini, menyatakan setuju untuk ikut dalam penelitian ini secara sukarela tanpa paksaan.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini. Saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh peneliti. Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data saya yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Dengan membubuhkan tandatangan saya di bawah ini, saya menegaskan keikutsertaan saya secara sukarela dalam studi penelitian ini.

	Nama	**Tanda tangan**	**Tgl/Bln/Thn**
Responden	.....	.....	.....
/Wali			
Saksi	.....	.....	.....

(Tanda Tangan Saksi diperlukan hanya jika Partisipan tidak dapat memberikan consent/persetujuan sehingga menggunakan wali yang sah secara hukum, yaitu untuk partisipan berikut:

1. Berusia di bawah 18 tahun
2. Usia lanjut
3. Gangguan mental
4. Pasien tidak sadar
5. Dan lain-lain kondisi yang tidak memungkinkan memberikan persetujuan

Penanggung jawab penelitian :
Nama : dr. Ade Septriana
Alamat : Jalan Hertasning,
Komplek Griya Hertamas Blok B/15,
Kota Makassar
Tlp : 081234350012

Penanggung jawab Medis :

Lampiran 3. Statistik Penelitian

Karaktersitik Sampel

Jenis_Kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	6	33,3	33,3	33,3
	Perempuan	12	66,7	66,7	100,0
	Total	18	100,0	100,0	

Usia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	12-25 tahun	3	16,7	16,7	16,7
	26-45 tahun	7	38,9	38,9	55,6
	46-65 tahun	8	44,4	44,4	100,0
	Total	18	100,0	100,0	

Skor CAS Pre dan Post Pemberian Kortikosteroid Intravena

CAS_Pre * CAS_Post Crosstabulation

			CAS_Post		
			Active	Pasive	Total
CAS_Pre	Active	Count	4	12	16
		% of Total	22,2%	66,7%	88,9%
	Pasive	Count	0	2	2
		% of Total	0,0%	11,1%	11,1%
Total		Count	4	14	18
		% of Total	22,2%	77,8%	100,0%

Test Statistics[a]

	CAS_Pre & CAS_Post
N	18
Exact Sig. (2-tailed)	,000[b]

a. McNemar Test

b. Binomial distribution used.

Skor EUGOGO Pre dan Post Pemberian Kortikosteroid Intravena

EUGOGO_Pre * EUGOGO_Post Crosstabulation

			EUGOGO_Post			
			Mild	Moderate to Severe	Sight Treatening	Total
EUGOGO_Pre	Mild	Count	7	0	0	7
		% of Total	38,9%	0,0%	0,0%	38,9%
	Moderate to Severe	Count	1	6	0	7
		% of Total	5,6%	33,3%	0,0%	38,9%
	Sight Treatening	Count	0	2	2	4
		% of Total	0,0%	11,1%	11,1%	22,2%
Total		Count	8	8	2	18
		% of Total	44,4%	44,4%	11,1%	100,0%

Marginal Homogeneity Test

	EUGOGO_Pre & EUGOGO_Post
Distinct Values	3
Off-Diagonal Cases	3
Observed MH Statistic	8,000
Mean MH Statistic	6,500
Std. Deviation of MH Statistic	,866
Std. MH Statistic	1,732
Asymp. Sig. (2-tailed)	,083

Analisa Skor Kualitas Hidup QoL dan Apperance

Report

	Qol_pre	Qol_post	Appearence_pre	Appearence_Post
Mean	10,7222	10,6111	22,9167	19,7917
N	18	18	18	18
Std. Deviation	5,00359	5,01924	30,91735	31,66997

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Qol_pre	,412	18	,000	,587	18	,000
Qol_post	,459	18	,000	,553	18	,000
Appearence_pre	,276	18	,001	,757	18	,000
Appearence_Post	,332	18	,000	,678	18	,000

a. Lilliefors Significance Correction

Ranks

		N	Mean Rank	Sum of Ranks
Qol_post - Qol_pre	Negative Ranks	1[a]	1,00	1,00
	Positive Ranks	0[b]	,00	,00
	Ties	17[c]		
	Total	18		
Appearence_Post - Appearence_pre	Negative Ranks	7[d]	4,00	28,00
	Positive Ranks	0[e]	,00	,00
	Ties	11[f]		
	Total	18		

a. Qol_post < Qol_pre

b. Qol_post > Qol_pre

c. Qol_post = Qol_pre

d. Appearence_Post < Appearence_pre

e. Appearence_Post > Appearence_pre

f. Appearence_Post = Appearence_pre

Test Statistics[a]

	Qol_post - Qol_pre	Appearence_Post - Appearence_pre
Z	-1,000[b]	-2,460[b]
Asymp. Sig. (2-tailed)	,317	,014

a. Wilcoxon Signed Ranks Test

b. Based on positive ranks.

Lampiran 4. Master Data Penelitian

Nama	Jenis Kelamin		Visus		Gejala Klinis					Soft Tissue Involvement / CAS										CAS SCORE	Interpreta	Riwayat Merokok	EUGOGO
Pretest		Usia	OD	OS	Proptosis	Retraksi K	Diplopia	Nyeri	Pengliha	Nyeri Orb	Nyeri Ger	Edema Pa	Eritema P	Injeksi Ko	Kemosis K	Inflamasi	Proptosis	Penuruna	Penurunan Visus 1 baris				
Syarif	P	31	20/50	20/50	V	V	v	v	v	1	1	1	0	0	0	1	0	0	0	4	Active	Tidak	Mild TED
Asriac	L	56	1/300	20/40	V	V	X	V	V	1	0	1	0	0	0	1	0	0	0	3	Active	Ada	Sight Treatening
Nelvi	P	20	20/200 KH	20/200 KH	V	X	X	V	X	1	0	1	0	0	0	1	0	0	0	3	Active	Pasif	Mild TED
Stefar	L	56	20/400	20/400	V	V	X	X	V	0	0	1	0	1	0	1	0	0	0	3	Active	Ada	Mild TED
Khadi	P	21	20/30	20/40	X	X	X	V	X	1	0	1	1	0	0	0	0	0	0	3	Active	Tidak	Mild TED
Andi A	P	49	20/30	20/30	V	V	X	V	X	1	0	1	1	0	0	0	0	0	0	3	Active	Tidak	Mild TED
Haeru	L	53	20/25	20/20	V	V	X	V	X	1	0	1	0	0	0	1	0	0	0	3	Active	Ada	Moderate to severe TED
Ulfa D	P	28	20/20	20/20	V	X	X	X	X	0	0	1	0	1	0	1	0	0	0	3	Active	Tidak	Mild TED
Muha	L	60	20/60	2/60	V	X	V	X	V	1	1	1	0	1	1	1	0	0	0	6	Active	Ya	Sight Treatening
Nursia	L	33	20/200	20/200	V	X	X	X	X	0	0	0	0	0	0	0	1	0	0	1	Inactive	Tidak	Moderate to severe TED
Nelly	P	42	20/50	20/25	V	X	X	V	X	1	0	1	1	1	0	0	0	0	0	4	Active	Tidak	Moderate to severe TED
Basir	L	50	20/60	1/300	V	V	X	V	V	1	1	1	0	1	1	1	0	0	0	6	Active	Ya	Sight Treatening
Musa	P	33	20/60	20/25	V	X	V	V	V	1	0	1	0	1	0	0	0	0	0	3	Active	Tidak	Moderate to severe TED
Mardi	P	39	20/50	20/30	V	X	X	V	X	1	0	1	1	0	0	0	0	0	0	3	Active	Tidak	Mild TED
Ike He	P	49	20/40	20/30	V	X	X	V	X	1	1	1	0	0	0	0	0	0	0	3	Active	Tidak	Moderate to severe TED
Afriya	P	43	20/25	20/40	V	X	X	X	X	0	0	1	1	1	1	0	0	0	0	4	Active	Tidak	Moderate to severe TED
Alifia	P	22	20/25	20/30	V	X	X	X	X	1	1	1	1	1	0	0	0	0	0	5	Active	Tidak	Moderate to severe TED
Sutina	P	43	20/25	20/400	V	V	X	X	V	0	0	0	0	0	0	0	1	1	0	2	Inactive	Tidak	Sight Treatening
Postest																							
Syarif	P	31	20/25	20/25	V	V	v	v	v	0	0	1	0	0	0	1	0	0	0	2	Inactive	Tidak	Mild TED
Asriac	L	56	1/300	3/60	V	V	X	V	V	1	0	1	0	0	0	1	1	1	1	6	Active	Ada	Sight Treatening
Nelvi	P	20	20/20	20/20	V	X	X	X	X	0	0	1	0	0	0	1	0	0	0	2	Inactive	Pasif	Mild TED
Stefar	L	56	20/60	20/120	v	v	x	x	v	0	0	1	0	0	0	1	0	0	0	2	Inactive	Ada	Mild TED
Khadi	P	21	20/20	20/20	X	X	X	X	X	0	0	1	0	0	0	0	0	0	0	1	Inactive	Tidak	Mild TED
Andi A	P	49	20/25	20/25	V	V	X	X	X	0	0	1	0	0	0	0	0	0	0	1	Inactive	Tidak	Mild TED
Haeru	L	53	20/20	20/20	V	V	X	X	X	0	0	0	0	0	0	1	1	1	0	3	Inactive	Ada	Moderate to severe TED
Ulfa D	P	28	20/20	20/20	V	X	X	X	X	0	0	0	0	0	0	0	1	0	0	1	Inactive	Tidak	Mild TED
Muha	L	60	20/20	20/30	X	X	V	X	X	1	1	1	0	0	0	0	1	0	0	4	Active	Ya	Moderate to severe TED
Nursia	P	33	20/20	20/20	V	X	X	X	X	0	0	0	0	0	0	1	0	0	0	1	Inactive	Tidak	Moderate to severe TED
Nelly	P	42	20/30	20/20	V	X	X	V	X	1	0	0	0	0	0	0	0	0	0	1	Inactive	Tidak	Mild TED
Basir	L	50	20/40	2/60	V	V	X	V	V	1	0	1	0	0	0	1	1	0	0	4	Active	Ya	Sight Treatening
Musa	P	33	20/20	20/20	V	X	V	V	X	1	0	1	0	1	0	1	0	1	0	5	Active	Tidak	Moderate to severe TED
Mardi	P	39	20/25	20/30	V	X	X	X	X	0	0	0	0	0	0	1	0	0	0	1	Inactive	Tidak	Mild TED
Ike He	P	49	20/25	20/30	V	X	X	X	X	1	0	1	0	1	0	0	0	0	0	3	Inactive	Ya	Moderate to severe TED
Afriya	P	43	20/20	20/30	V	X	X	X	X	0	0	1	0	1	0	0	0	0	0	2	Inactive	Tidak	Moderate to severe TED
Alifia	P	22	20/25	20/20	V	X	X	X	X	0	0	1	0	0	0	0	0	0	0	1	Inactive	Ya	Moderate to severe TED
Sutina	P	43	20/50	20/400	V	V	X	X	X	0	0	0	0	0	0	0	0	0	0	0	Inactive	Tidak	Moderate to severe TED

No	Nama	Jenis Kelar	RM	Tgl lahir		Quality Of Life																										Jumlah	Total Skor
						1		2		3		4		5		6		7		8															
1	Syarifah Ba	P	882387	33896	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
3	Asriadi	L	893780	29068	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOSULY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SEVERELY	3	24	100												
5	Nelvi Must	P	886246	37915	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
7	Stefanus	L	970047	24654	3	LITTLE	2	LITTLE	2	NO	1	NO	1	NO	1	NO	1	LITTLE	1	LITTLE	2	11	18,75												
9	Khadijah	P	956219	37511	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
11	Andi Agusi	P	447860	27263	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
13	Haerun	L	932390	25751	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
15	Ulfa Dwi N	P	926637	34838	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
17	Muhamma	L	943421	23074	3	SERIOUSLY	3	SERIOUSLY	3	LITTLE	2	LITTLE	2	SERIOUSLY	3	LITTLE	2	LITTLE	2	SEVERELY	3	20	75												
19	Nursiah	L	9423135	33200	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
21	Nelly Kary	P	969331	29947	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
23	Basir	L	179553	26987	3	SERIOUSLY	3	SERIOUSLY	3	LITTLE	2	LITTLE	2	SERIOUSLY	3	LITTLE	2	LITTLE	2	SEVERELY	3	20	75												
25	Musayyan	P	991001	33004	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
27	Mardiah	P	986904	30751	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
29	Ike Heriyar	P	941220	27153	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
31	Afriyanty B	P	984041	15/4/1980	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
33	Alifia Putri	P	942324	20/2/2001	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
35	Sutina Sula	P	990779	29504	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
2	Syarifah Ba	P	882387	33896	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
4	Asriadi	L	893780	29068	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOSULY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SEVERELY	3	24	100												
6	Nelvi Must	P	886246	37915	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
8	Stefanus	L	970047	24654	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
10	Khadijah	P	956219	37511	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
12	Andi Agusi	P	447860	27263	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
14	Haerun	L	932390	25751	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
16	Ulfa Dwi N	P	926637	34838	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
18	Muhamma	L	943421	23074	2	SERIOUSLY	3	SERIOUSLY	3	LITTLE	2	LITTLE	2	SERIOUSLY	3	LITTLE	2	LITTLE	2	SEVERELY	3	20	75												
20	Nursiah	P	944777	37233	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
22	Nelly Kary	P	969331	29947	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
24	Basir	L	179553	26987	3	SERIOUSLY	3	SERIOUSLY	3	LITTLE	2	LITTLE	2	SERIOUSLY	3	LITTLE	2	LITTLE	2	SEVERELY	3	20	75												
26	Musayyan	P	991001	33004	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
28	Mardiah	P	986904	30751	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
30	Ike Heriyar	P	941220	27153	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												
32	Afriyanty B	P	984041	15/4/1980	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
34	Alifia Putri	P	942324	20/2/2001	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	8	0												
36	Sutina Sula	P	990779	29504	2	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	9	6,25												

No	Nama	Jenis Kelar	RM	Tgl lahir	Following questions deal with your TED in general (Appearance)																										Jumlah	Total Skor
					9		10		11		12		13		14		15		16															
1	Syarifah Ba	P	882387	33896	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
3	Asriadi	L	893780	29068	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3											24	100
5	Nelvi Must	P	886246	37915	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
7	Stefanus	L	970047	24654	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	2	NO	1	LITTLE	2	NO	1											14	37,5
9	Khadijah	P	956219	37511	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
11	Andi Agusr	P	447860	27263	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
13	Haerun	L	932390	25751	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
15	Ulfa Dwi N	P	926637	34838	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	NO	1											9	6,25
17	Muhamma	L	943421	23074	SERIOUSLY	3	LITTLE	2	LITTLE	2	LITTLE	2	SERIOUSLY	3	SERIOUSLY	3	LITTLE	2	SERIOUSLY	3											20	75
19	Nursiah	L	9423135	33200	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
21	Nelly Kary	P	969331	29947	NO	1	NO	1	NO	1	NO	1	LITTLE	2	LITTLE	2	LITTLE	2	NO	1											11	18,75
23	Basir	L	179553	26987	SERIOUSLY	3	LITTLE	2	LITTLE	2	LITTLE	2	SERIOUSLY	3	SERIOUSLY	3	LITTLE	2	SERIOUSLY	3											20	75
25	Musayyana	P	991001	33004	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	LITTLE	2	NO	1											10	12,5
27	Mardiah	P	986904	30751	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	NO	1											9	6,25
29	Ike Heriyar	P	941220	27153	LITTLE	2	NO	1	NO	1	NO	1	NO	1	LITTLE	2	LITTLE	2	NO	1											11	18,75
31	Afriyanty B	P	984041	15/4/1980	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	NO	1											9	6,25
33	Alifia Putri	P	942324	20/2/2001	LITTLE	2	NO	1	NO	1	NO	1	NO	1	LITTLE	2	NO	1	NO	1											10	12,5
35	Sutina Sula	P	990779	29504	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	2	NO	1											15	43,75
2	Syarifah Ba	P	882387	33896	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
4	Asriadi	L	893780	29068	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3	SERIOUSLY	3											24	100
6	Nelvi Must	P	886246	37915	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
8	Stefanus	L	970047	24654	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	1	NO	1	NO	1	LITTLE	2	NO	1											12	25
10	Khadijah	P	956219	37511	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
12	Andi Agusr	P	447860	27263	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
14	Haerun	L	932390	25751	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
16	Ulfa Dwi N	P	926637	34838	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
18	Muhamma	L	943421	23074	SERIOUSLY	3	LITTLE	2	LITTLE	2	LITTLE	2	SERIOUSLY	3	SERIOUSLY	3	LITTLE	2	SERIOUSLY	3											20	75
20	Nursiah	P	944777	37233	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
22	Nelly Kary	P	969331	29947	NO	1	NO	1	NO	1	NO	1	LITTLE	2	LITTLE	2	NO	1	NO	1											10	12,5
24	Basir	L	179553	26987	SERIOUSLY	3	LITTLE	2	LITTLE	2	LITTLE	2	SERIOUSLY	3	SERIOUSLY	3	LITTLE	2	SERIOUSLY	3											20	75
26	Musayyana	P	991001	33004	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	NO	1											9	6,25
28	Mardiah	P	986904	30751	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1											8	0
30	Ike Heriyar	P	941220	27153	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	NO	1											9	6,25
32	Afriyanty B	P	984041	15/4/1980	NO	1	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	NO	1											9	6,25
34	Alifia Putri	P	942324	20/2/2001	NO	1	NO	1	NO	1	NO	1	NO	1	LITTLE	2	NO	1	NO	1											9	6,25
36	Sutina Sula	P	990779	29504	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	2	LITTLE	2	NO	1											15	43,75